Corona Virus
Stay Safe, FollowGuidance
Fetching Location Data…
Vivek Kumar
Assorted Milka chocolates, mondelez

Mondelez International, one of the world’s largest snack companies, forecasts profit to grow over 5% this year and reported its net revenues increased 4.9% in the third quarter as people stuck at home during the coronavirus pandemic stocked cookies and chocolates, sending its shares up over 2% on Monday.

Manufacturer of Oreo cookies and Cadbury chocolates said its diluted EPS in the third quarter was $0.78, down 20.4%, lapping a prior-year benefit from Swiss tax reform; Adjusted EPS in the quarter was $0.63, flat on a constant-currency basis. That was in line with market expectations.

On the year-to-date basis, diluted EPS was $1.66, down 24.2%, lapping a prior-year benefit from Swiss tax reform and Adjusted EPS was $1.92, up 5.9% on a constant-currency basis.

For 2020, Mondelez forecasts organic net revenue to grow more than 3.5% and expects adjusted EPS growth of over 5% on a constant-currency basis. The company estimates currency translation would decrease 2020 net revenue growth by nearly 3% with a negative $0.04 impact to Adjusted EPS.

“With 2021 suggested to be another on-algo year despite accelerating brand investment, we continue to favour the stock, as Mondelez remains a stable globally diversified compounder trading at a discount to other multinational CPG companies,” said Rob Dickerson, equity analyst at Jefferies.

“Stock still has upside given end-market positioning, efficiency gains, and liquidity vis-a-vis valuation. Topline growth seems sustainable longer-term given end-market exposure, liquidity and leverage remain healthy, global share trends impressive, and emerging market trends increasingly reassuring, yet valuation is still discounted relative to other larger CPG multinationals. We continue to see 15%+ upside in the stock over the NTM, as long as the unknowns (COVID, Brexit, and U.S. tax policy) prove to be limited shocks,” Dickerson added.

Mondelez shares closed 2.29% higher at $54.34 on Monday; however, the stock is down around 1% so far this year.

Executive Comments

“Our third-quarter performance was strong across all key metrics, with broad-based revenue growth as demand remained elevated in Developed Markets and sequentially improved in Emerging Markets,” said Dirk Van de Put, Chairman and Chief Executive Officer.

“Our strategy remains unchanged and we are accelerating certain initiatives and increasing the investment behind our brands to further support long-term sustainable growth.”


Mondelez Stock Price Forecast

Six equity analysts forecast the average price in 12 months at $64.50 with a high forecast of $68.00 and a low forecast of $60.00. The average price target represents an 18.70% increase from the last price of $54.34. From those six analysts, five rated “Buy”, one rated “Hold” and none rated “Sell”, according to Tipranks.

Morgan Stanley gave the base target price of $63 with a high of $75 under a bull-case scenario and $39 under the worst-case scenario. The firm currently has an “Overweight” rating on the world’s largest snack company’s stock. Jefferies Financial Group raised their target price on Mondelez International to $64 from $60 and gave the company a “buy” rating. Barclays restated a “buy” rating and set a $62 target price.

Several other analysts have also recently commented on the stock. Piper Sandler raised their target price to $66 from $60 and gave the company an “overweight” rating. Seaport Global Securities set a “buy” rating and a $61 target price. At last, Sanford C. Bernstein restated a “buy” rating.

Analyst Comments

“Mondelez (MDLZ) is our top pick in food. We believe MDLZ’s long-term organic sales growth has accelerated sustainably to the ~3.5% level after an expected COVID depressed 2020 at 3%, driven by: (1) Favorable geographic/category exposure (emerging markets and snacking categories); (2) strategic changes (focus on local brands and topline expansion, changes in incentive comp); (3) market share trends improving from higher investment and supply chain benefits; and (4) US topline growth trends accelerating with strong market share,” said Dara Mohsenian, equity analyst at Morgan Stanley.

“We argue MDLZ’s topline/EPS growth profile is more similar to mega-cap CPG peers (KO/PEP/PG/CL), and valuation looks compelling at a nearly ~20% discount to mega-cap CPG peers.,” Mohsenian added.

Check out FX Empire’s earnings calendar

Don't miss a thing!
Discover what's moving the markets. Sign up for a daily update delivered to your inbox

Trade With A Regulated Broker

  • Your capital is at risk
The content provided on the website includes general news and publications, our personal analysis and opinions, and contents provided by third parties, which are intended for educational and research purposes only. It does not constitute, and should not be read as, any recommendation or advice to take any action whatsoever, including to make any investment or buy any product. When making any financial decision, you should perform your own due diligence checks, apply your own discretion and consult your competent advisors. The content of the website is not personally directed to you, and we does not take into account your financial situation or needs.The information contained in this website is not necessarily provided in real-time nor is it necessarily accurate. Prices provided herein may be provided by market makers and not by exchanges.Any trading or other financial decision you make shall be at your full responsibility, and you must not rely on any information provided through the website. FX Empire does not provide any warranty regarding any of the information contained in the website, and shall bear no responsibility for any trading losses you might incur as a result of using any information contained in the website.The website may include advertisements and other promotional contents, and FX Empire may receive compensation from third parties in connection with the content. FX Empire does not endorse any third party or recommends using any third party's services, and does not assume responsibility for your use of any such third party's website or services.FX Empire and its employees, officers, subsidiaries and associates, are not liable nor shall they be held liable for any loss or damage resulting from your use of the website or reliance on the information provided on this website.
This website includes information about cryptocurrencies, contracts for difference (CFDs) and other financial instruments, and about brokers, exchanges and other entities trading in such instruments. Both cryptocurrencies and CFDs are complex instruments and come with a high risk of losing money. You should carefully consider whether you understand how these instruments work and whether you can afford to take the high risk of losing your money.FX Empire encourages you to perform your own research before making any investment decision, and to avoid investing in any financial instrument which you do not fully understand how it works and what are the risks involved.